Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril

European Journal of Clinical Pharmacology

Volumn 47, Issue 6, 1995, Pages 513-518

  van Griensven, J M T ^a   Schoemaker, R C ^a   Cohen, A F ^a   Luus, H G ^b   Seibert Grafe, M ^c   Rothig H J ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

^c SANOFI   (France)

Author keywords

bioavailability; healthy volunteers; Ramipril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; RAMIPRIL; RAMIPRILAT;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; KIDNEY; MALE; PEPTIDYL-DIPEPTIDASE A; RAMIPRIL;

EID: 0028956587     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/BF00193704     Document Type: Article

References (25)

1. The effect of ramipril on ambulatory blood pressure: a multicenter trial
2. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension
3. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE)
4. Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency
5. The effect of ramipril, a new angiotensin-converting enzyme inhibitor, on cortical nephron flow and effective renal plasma flow in patients with essential hypertension
6. Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure
7. The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension
8. Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III–IV)
9. Global and regional hemodynamic effects of ramipril in congestive heart failure
10. Antihypertensive efficacy, tolerance and safety of long-term treatment with ramipril in patients with mild-to-moderate essential hypertension
11. Tolerability of ramipril in a multicenter of mild-to-moderate hypertension in general practice
12. Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats
13. Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study
14. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor
15. Steady-state kinetics of ramipril in renal failure
16. In vitro tissue potencies of converting enzyme inhibitors. Prodrug activation by kidney esterase
17. Effects on autonomic function of a new angiotensin converting enzyme inhibitor, ramipril
18. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension
19. Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders
20. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects
21. A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite
22. Eine empfindliche Methode zur Bestimming des ACE-Hemmers HOE 498 und dessen Metaboliten in Humanurin mittels Capillarsäulen-Gas-Chromatographie
23. Effect of angiotensin-converting enzyme inhibition on human tissue renin
24. The pharmacokinetics and bioavailability of cilizapril in normal man
25. Age and the pharmacokinetics of angiotensin converting anzyme inhibitors enalapril and enalaprilat